MX2022012505A - Composiciones y metodos de uso de inhibidores de tirosina quinasa. - Google Patents
Composiciones y metodos de uso de inhibidores de tirosina quinasa.Info
- Publication number
- MX2022012505A MX2022012505A MX2022012505A MX2022012505A MX2022012505A MX 2022012505 A MX2022012505 A MX 2022012505A MX 2022012505 A MX2022012505 A MX 2022012505A MX 2022012505 A MX2022012505 A MX 2022012505A MX 2022012505 A MX2022012505 A MX 2022012505A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- tyrosine kinase
- phosphorylation
- compositions
- tyrosine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 3
- 230000026731 phosphorylation Effects 0.000 abstract 4
- 238000006366 phosphorylation reaction Methods 0.000 abstract 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 3
- 102100021270 Myelin protein zero-like protein 1 Human genes 0.000 abstract 2
- 108050004033 Myelin protein zero-like protein 1 Proteins 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000002330 Congenital Heart Defects Diseases 0.000 abstract 1
- 208000005101 LEOPARD Syndrome Diseases 0.000 abstract 1
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 abstract 1
- 208000029567 RASopathy Diseases 0.000 abstract 1
- 208000028831 congenital heart disease Diseases 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona composiciones y métodos para inhibir la fosforilación de tirosina; en un aspecto, una composición incluye incluir un inhibidor de tirosina quinasa de dosis baja, donde el inhibidor de tirosina quinasa de dosis baja disminuye la fosforilación de tirosina; en otro aspecto, se describe un método para tratar una enfermedad o afección cardiovascular asociada con una RASopatía que tiene una fosforilación aberrante de la proteína tirosina; también se describen métodos para tratar la cardiopatía congénita asociada con el síndrome de Noonan o síndrome de Noonan con múltiples lentigos y disminución de los niveles aberrantes de la fosforilación de tirosilo de la proteína cero relacionada (PZR).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107553P | 2015-01-26 | 2015-01-26 | |
| US201562250052P | 2015-11-03 | 2015-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012505A true MX2022012505A (es) | 2022-11-07 |
Family
ID=56544226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009643A MX2017009643A (es) | 2015-01-26 | 2016-01-26 | Composiciones y métodos de uso de inhibidores de tirosina quinasa. |
| MX2022012505A MX2022012505A (es) | 2015-01-26 | 2017-07-25 | Composiciones y metodos de uso de inhibidores de tirosina quinasa. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009643A MX2017009643A (es) | 2015-01-26 | 2016-01-26 | Composiciones y métodos de uso de inhibidores de tirosina quinasa. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10471059B2 (es) |
| EP (1) | EP3250192A4 (es) |
| JP (3) | JP6854766B2 (es) |
| CN (2) | CN113244399A (es) |
| CA (1) | CA2974958A1 (es) |
| HK (1) | HK1245678A1 (es) |
| MX (2) | MX2017009643A (es) |
| WO (1) | WO2016123086A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CN106943595A (zh) * | 2017-03-30 | 2017-07-14 | 福州大学 | Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用 |
| EP3823615A4 (en) * | 2018-06-18 | 2022-04-06 | Duke University | COMPOSITIONS AND METHODS OF TREATMENT OF DISORDERS CHARACTERIZED BY ABERRANTE RAS/MAPK SIGNALING |
| US20220117966A1 (en) * | 2019-02-27 | 2022-04-21 | Astrazeneca Ab | Method of treating fibrosis |
| WO2021119525A1 (en) * | 2019-12-11 | 2021-06-17 | Tiaki Therapeutics Inc. | Shp1 and shp2 inhibitors and their methods of use |
| US20240075031A1 (en) * | 2020-12-07 | 2024-03-07 | Hht Foundation International, Inc. | Method of treating hereditary hemorrhagic telangiectasia using pazopanib |
| WO2023127012A1 (ja) * | 2021-12-27 | 2023-07-06 | 国立研究開発法人理化学研究所 | 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法 |
| WO2023175136A1 (en) * | 2022-03-18 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355786B1 (en) | 1998-10-30 | 2002-03-12 | Vanderbilt University | Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same |
| WO2001034201A2 (en) * | 1999-11-12 | 2001-05-17 | Advanced Research And Technology Institute, Inc. | Methods for inhibiting neurofibromatosis type 1 (nf1) |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| CA2579519A1 (en) | 2004-09-09 | 2006-03-16 | The General Hospital Corporation | Modulating phosphatase activity in cardiac cells |
| WO2007011757A1 (en) | 2005-07-14 | 2007-01-25 | Myogen, Inc. | Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
| US20070123539A1 (en) * | 2005-10-20 | 2007-05-31 | University Of South Florida | Treatment of Restenosis and Stenosis with Dasatinib |
| GB0609962D0 (en) | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| CN103463621B (zh) * | 2006-10-31 | 2016-01-06 | 托莱多大学 | Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂 |
| US8865692B2 (en) * | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
| EP2359813A1 (en) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
| AU2014205481A1 (en) * | 2013-01-10 | 2015-08-27 | Gilead Sciences, Inc. | Therapeutic indications of kinase inhibitors |
| CA2917667A1 (en) * | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
-
2016
- 2016-01-26 JP JP2017539224A patent/JP6854766B2/ja active Active
- 2016-01-26 CA CA2974958A patent/CA2974958A1/en active Pending
- 2016-01-26 EP EP16743949.6A patent/EP3250192A4/en active Pending
- 2016-01-26 CN CN202110533185.2A patent/CN113244399A/zh active Pending
- 2016-01-26 MX MX2017009643A patent/MX2017009643A/es unknown
- 2016-01-26 CN CN201680018121.6A patent/CN107530298B/zh active Active
- 2016-01-26 WO PCT/US2016/014882 patent/WO2016123086A1/en active Application Filing
- 2016-01-26 US US15/544,401 patent/US10471059B2/en active Active
-
2017
- 2017-07-25 MX MX2022012505A patent/MX2022012505A/es unknown
-
2018
- 2018-04-27 HK HK18105513.7A patent/HK1245678A1/zh unknown
-
2019
- 2019-09-19 US US16/575,637 patent/US11458137B2/en active Active
-
2020
- 2020-12-02 JP JP2020200158A patent/JP2021050218A/ja active Pending
-
2022
- 2022-08-30 US US17/823,439 patent/US20230036788A1/en active Pending
-
2023
- 2023-02-03 JP JP2023015070A patent/JP2023052878A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200009142A1 (en) | 2020-01-09 |
| EP3250192A1 (en) | 2017-12-06 |
| JP2018504416A (ja) | 2018-02-15 |
| CN107530298A (zh) | 2018-01-02 |
| JP2021050218A (ja) | 2021-04-01 |
| JP6854766B2 (ja) | 2021-04-07 |
| WO2016123086A1 (en) | 2016-08-04 |
| JP2023052878A (ja) | 2023-04-12 |
| US20230036788A1 (en) | 2023-02-02 |
| US20180271864A1 (en) | 2018-09-27 |
| CN107530298B (zh) | 2021-06-04 |
| CN113244399A (zh) | 2021-08-13 |
| US11458137B2 (en) | 2022-10-04 |
| HK1245678A1 (zh) | 2018-08-31 |
| MX2017009643A (es) | 2018-05-04 |
| US10471059B2 (en) | 2019-11-12 |
| EP3250192A4 (en) | 2018-09-26 |
| CA2974958A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012505A (es) | Composiciones y metodos de uso de inhibidores de tirosina quinasa. | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MY189941A (en) | Pyrazole compounds and method for making and using the compounds | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018006287A (es) | Inhibidores de acc de triazol y usos de los mismos. | |
| MX2018006286A (es) | Inhibidores de acc pirazolicos y usos de los mismos. | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
| MX2016012829A (es) | Inhibidores de biaril cinasa. | |
| MX2018007155A (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj). | |
| WO2007115289A8 (en) | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer | |
| IL282801A (en) | Compounds, pharmaceutical compounds, and methods of making compounds and using them as ATR kinase inhibitors | |
| IL283599A (en) | Tyrosine kinase inhibitors, preparations and methods | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
| IL281805A (en) | Quinazoline derivatives as tyrosine kinase inhibitors, preparations, methods for their preparation and use | |
| MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| EP4295910A3 (en) | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity | |
| MX2010001813A (es) | Metodos y composiciones para el tratamiento de canceres. | |
| MY201291A (en) | Aminothiazole compounds as protein kinase inhibitors | |
| WO2017035176A8 (en) | Method of preventing or treating obesity with an emc10 inhibitor |